MENU
+Compare
AKBA
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$3.65
Change
-$0.09 (-2.41%)
Capitalization
958.62M

AKBA Akebia Therapeutics Forecast, Technical & Fundamental Analysis

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more

Industry: #Biotechnology
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AKBA with price predictions
Jun 27, 2025

Aroon Indicator for AKBA shows an upward move is likely

AKBA's Aroon Indicator triggered a bullish signal on June 18, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 181 similar instances where the Aroon Indicator showed a similar pattern. In of the 181 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 26, 2025. You may want to consider a long position or call options on AKBA as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AKBA moved out of overbought territory on June 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for AKBA turned negative on June 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

AKBA broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.062) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). AKBA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (4.344) is also within normal values, averaging (252.247).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AKBA is expected to report earnings to fall 166.67% to -1 cents per share on July 31

Akebia Therapeutics AKBA Stock Earnings Reports
Q2'25
Est.
$-0.02
Q1'25
Beat
by $0.08
Q4'24
Missed
by $0.03
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.03
The last earnings report on May 08 showed earnings per share of 2 cents, beating the estimate of -5 cents. With 2.30K shares outstanding, the current market capitalization sits at 958.62M.
A.I. Advisor
published General Information

General Information

a developer of drugs for the treatment of anemia and vascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
245 First Street
Phone
+1 617 871-2098
Employees
167
Web
https://www.akebia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MUIFX32.310.21
+0.65%
Nationwide Institutional Service
EFCNX22.560.11
+0.49%
Emerald Insights Investor
PMGJX8.070.02
+0.25%
Principal MidCap Growth J
DCCAX28.31-0.05
-0.18%
Macquarie Small Cap Core A
EKWCX75.21-3.32
-4.23%
Allspring Precious Metals C

AKBA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
N/A
XERS - AKBA
42%
Loosely correlated
-0.84%
HOWL - AKBA
40%
Loosely correlated
-10.53%
ATOS - AKBA
39%
Loosely correlated
+1.64%
IPSC - AKBA
39%
Loosely correlated
-5.74%
ADAP - AKBA
39%
Loosely correlated
+1.16%
More